Results 151 to 160 of about 66,239 (358)

Trends and Outcomes of Anticoagulation for Post‐Operative Atrial Fibrillation After Coronary Artery Bypass Graft

Pacing and Clinical Electrophysiology, EarlyView.
ABSTRACT Background The benefit of oral anticoagulation (OAC) in patients with new‐onset postoperative atrial fibrillation (POAF) after coronary bypass grafting remains uncertain. The 2023 American Heart Association (AHA) and the American College of Cardiology (ACC) guidelines recommend 60 days of anticoagulation for POAF, whereas management was ...
Daniel S. Cheah, Kathryn Tsai, Krishna Prasad Kurpad, Yousra Khalid, Sanjay S. Mehta   +4 more
wiley   +1 more source

Medication Utilization Evaluation of Dabigatran and Rivaroxaban within a Large, Multicenter Health System. [PDF]

, 2013
Objective. The objective of this medication utilization evaluation (MUE) was to determine the appropriateness of dabigatran and rivaroxaban while also reviewing outcomes for safety and effectiveness within a large, multi-center health system. Methods.
Doolin, Meagan, Issacs, Alex N., Morse, Courtney, Nisly, Sarah A., Shiltz, Erin   +4 more
core   +1 more source

Global Prospective Safety Analysis of Rivaroxaban. [PDF]

, 2018
BACKGROUND: The efficacy of direct oral anticoagulants (DOACs) for stroke prevention in patients with atrial fibrillation (AF) has been established in clinical trials.
A. John Camm, Alexander G.G. Turpie, Camm, Camm, Camm, Camm, Chugh, Coleman, Coleman, Connolly, Fernando Lanas, Ghazi Radaideh, Giugliano, Granger, Healey, Hecker, January, Jose, Kirchhof, Kirchhof, Kirchhof, Ligthelm, Lip, Marc Lambelet, Miriam Bach, Nieuwlaat, Patel, Paulus Kirchhof, Peacock, Pierre Amarenco, Ruff, Steinberg, Sun, Susanne Hess, Sylvia Haas, Tsai, Wong, Young-Hoon Kim, Zoni-Berisso   +38 more
core   +2 more sources

Pharmacodynamic and pharmacokinetic basics of rivaroxaban [PDF]

Fundamental & Clinical Pharmacology, 2011
AbstractRivaroxaban, an oral, direct factor Xa inhibitor, is a small molecule drug capable of inhibiting not only free factor Xa with high selectivity but also prothrombinase‐bound and clot‐associated factor Xa in a concentration‐dependent manner. Clinical studies have demonstrated predictable anticoagulation and confirmed dose‐proportional effects for
openaire   +2 more sources

Cellular and molecular cross‐talk in atrial fibrillation: The role of non‐cardiomyocytes in creating an arrhythmogenic substrate

The Journal of Physiology, EarlyView.
Abstract figure legend Illustration of cellular and molecular cross‐talk in atrial fibrillation. Left: a schematic of cardiac tissue showing cardiomyocytes, fibroblasts, adipocytes, inflammatory cells and the coagulation system. Right: direct and indirect cross‐talk between different cell types, with the impact of direct cross‐talk on action potential (
Zhenyu Dong, Ruben Coronel, Joris R. de Groot   +2 more
wiley   +1 more source

In Vivo pharmacokinetic interactions of ribociclib with rivaroxaban and apixaban in rats: implications for increased drug exposure and dose adjustments

Frontiers in Pharmacology
BackgroundApixaban (API) and rivaroxaban (RIVA) are orally available inhibitors of coagulation factor Xa and are commonly used to treat cancer-related venous thrombosis.
Zihan Liu, Zihan Liu, Wenyu Du, Wenyu Du, Qimin Wang, Zhi Wang, Jing An, Yinling Ma, Zhanjun Dong, Ying Li   +9 more
doaj   +1 more source

The Risk of Colonoscopy‐related Bleeding in Patients With or Without Continued Treatment With an Antithrombotic Agent

DEN Open, Volume 6, Issue 1, April 2026.
ABSTRACT Objectives We prospectively investigated the risk of colonoscopy‐related bleeding in relation to antithrombotic treatment. Methods This prospective, observational, single‐center cohort study (NCT02594813) enrolled consecutive patients who underwent colonoscopy, including the removal of colorectal polyps, regardless of the continuation of ...
Emi Nonaka, Ichitaro Horiuchi, Akira Horiuchi, Satoshi Ukai, Noriko Takahata, Kimihiko Oishi   +5 more
wiley   +1 more source

Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study.

Journal of the American Society of Nephrology, 2019
BACKGROUND Vitamin K antagonists (VKAs), although commonly used to reduce thromboembolic risk in atrial fibrillation, have been incriminated as probable cause of accelerated vascular calcification (VC) in patients on hemodialysis.
A. D. De Vriese, R. Caluwé, L. Pyfferoen, D. De Bacquer, K. De Boeck, J. Delanote, D. de Surgeloose, Piet Van Hoenacker, B. Van Vlem, F. Verbeke   +9 more
semanticscholar   +1 more source

Bilateral abducens nerve palsy due to septic thrombophlebitis. [PDF]

, 2019
PurposeTo report a case of septic thrombophlebitis producing bilateral abducens nerve palsy.ObservationA 65 year-old woman with recent sinus surgery experienced the onset of horizontal diplopia during treatment for bacteremia. Computer tomography of head
Robbins, Shira L, Savino, Peter J, Vu, Vincent N   +2 more
core  

Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms [PDF]

, 2016
A growing body of evidence suggests that atrial fibrillation (AF) is associated with myocardial infarction (MI). However, incidence and management of MI in AF is still undefined. METHODS AND RESULTS: We searched MEDLINE via PubMed and Cochrane database
PASTORI, DANIELE, PIGNATELLI, Pasquale, Soliman, Elsayed Z, VIOLI, Francesco   +3 more
core   +1 more source